This application for renewal of the UW/FHCRC CFAR includes the University of Washington, Fred Hutchinson Cancer Research Center, Seattle BioMed, and Seattle Children's Hospital, Foundation and Research Institute, and international partner institutions. Our CFAR has over 560 faculty, pre- and postdoctoral trainees, and research scientists. Matching financial support for our CFAR from partner institutions equals 35% of CFAR Direct Costs. The highly interdisciplinary CFAR membership represents 12 of the 16 UW Schools and Colleges and all five FHCRC Divisions. Annual external HIV/AIDS research, training, and service program funding to our four CFAR partners currently exceeds $362 million, including $160 million for 148 awards from six of seven CFAR co-sponsoring NIH institutes, OAR and the Fogarty Center. This warrants effective coordination and communication by the CFAR to optimize the return on investment. Strategic research priorities for the future are (1) Prevent New HIV Infections;(2) Improve HIV Disease Outcomes;(3) Expand Basic Science Discovery Research;and (4) Reduce HIV-Related Health Disparities. To achieve these aims, our goals are (1) Develop a New Generation of Young Innovative HIV/AIDS Researchers;and (2) Provide infrastructure, resources, and incentives for Sustainable Interdisciplinary Translational Science. Ten proposed Cores (three new or completely restructured) and three new Scientific Working Groups (SWGs) emphasize (1) Clinical, Epidemiology, Health Services, and Health Economics Research;(2) Socio- Behavioral and Prevention Research;and (3) Basic Discovery Research, including Retrovirology, Immunology, and Molecular Profiling/Computational Biology. Each Core has individual-level and population-level components, domestic and international components, and collaborations within and external to our CFAR. For the twenty-sixth year of the UW/FHCRC CFAR, we will continue to be innovative. A multi-stage Strategic planning process led to: (1) Merging current Clinical Research and Clinical Retrovirology Cores to improve efficiency and reduce costs;(2) Replacing the Computational Biology Core with a new Molecular Profiling and Computational Biology Core that synergizes FHCRC and UW strengths;(3) Creating an AIDS-Associated Infections and Malignancies Core from a successful SWG;and (4) Launching three new SWGs to build upon strong UW/FHCRC programs for research on Substance Abuse and HIV/STI;Implementation Science;and Curative Therapies for HIV. Cross-CFAR Cores (Administration, Developmental, Biometrics, and International) will support and interact with every Core. The CFAR will support and provide added value for future local, national and international HIV/AIDS research priorities.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
2P30AI027757-26
Application #
8489472
Study Section
Special Emphasis Panel (ZAI1-UKS-A (J1))
Program Officer
Namkung, Ann S
Project Start
1997-03-01
Project End
2018-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
26
Fiscal Year
2013
Total Cost
$5,254,390
Indirect Cost
$1,407,185
Name
University of Washington
Department
Public Health & Prev Medicine
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Olwit, Connie; Mugaba, Maureen; Osingada, Charles Peter et al. (2018) Existence, triggers, and coping with chronic sorrow: a qualitative study of caretakers of children with sickle cell disease in a National Referral Hospital in Kampala, Uganda. BMC Psychol 6:50
Young, J; Smith, C; Teira, R et al. (2018) Antiretroviral pill count and clinical outcomes in treatment-naïve patients with HIV infection. HIV Med 19:132-142
Heffron, Renee; Mugo, Nelly; Hong, Ting et al. (2018) Pregnancy outcomes and infant growth among babies with in-utero exposure to tenofovir-based preexposure prophylaxis for HIV prevention. AIDS 32:1707-1713
Torres, Thiago S; Harrison, Linda J; La Rosa, Alberto M et al. (2018) Quality of life among HIV-infected individuals failing first-line antiretroviral therapy in resource-limited settings. AIDS Care 30:954-962
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150
Pyra, Maria; Brown, Elizabeth R; Haberer, Jessica E et al. (2018) Patterns of Oral PrEP Adherence and HIV Risk Among Eastern African Women in HIV Serodiscordant Partnerships. AIDS Behav :
LaCourse, Sylvia M; Cranmer, Lisa M; Bekker, Adrie et al. (2018) Symptom screening for active tuberculosis in pregnant women living with HIV. Cochrane Database Syst Rev 2018:
Edwards, Jessie K; Cole, Stephen R; Moore, Richard D et al. (2018) Sensitivity Analyses for Misclassification of Cause of Death in the Parametric G-Formula. Am J Epidemiol :
Wagner, Anjuli D; O?Malley, Gabrielle; Firdawsi, Olivia et al. (2018) Brief Report: Disclosure, Consent, Opportunity Costs, and Inaccurate Risk Assessment Deter Pediatric HIV Testing: A Mixed-Methods Study. J Acquir Immune Defic Syndr 77:393-399
Merlin, Jessica S; Long, Dustin; Becker, William C et al. (2018) Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes. J Acquir Immune Defic Syndr 79:77-82

Showing the most recent 10 out of 1275 publications